Openbookopenbook
Equity
Multicell Techs Inc(MCET)
USD --+0.00%
Reward33Low
Risk73High
📊75%Data
Thin -31% profit margin · Revenue growing 1480% YoY
MCET
+0.0 · +0.00%
USD · PINK
Multicell Techs Inc | Healthcare
Structurally Challenged
Market Cap:50009
ℹ️
Reward Rating
33
Low
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
73
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on MCET to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Multicell Techs Inc?

, a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications.

MCET · Verdict

Limited reward · high risk

MCET's standout is volatility; cash flow and balance sheet weigh on the picture.

Based on 88% data coverage

MCET · Verdict

What’s working & what to watch

Strengths 1

  • Volatility75/100

    Above average

Watchouts 4

  • Cash flow6/100

    -2207% free-cash-flow margin

  • Balance sheet14/100

    Current ratio 0.11

  • Growth15/100

    Rev -90.0% CAGR · earnings -94.0%

  • Profitability32/100

    -771% net margin · 0% ROE

Model-based scoring. For information only — not financial advice.

What is Multicell Techs Inc?

, a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 50.01K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (33)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap50.01K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0005
52 Week LowN/A
Last AnnualNovember
IPO DateN/A
IncorporatedUSA
Shares Outstanding5B
No. of Employees2
IndustryBiotechnology
ExchangePINK
Beta-55.475
CurrencyUSD
Websitewww.multicelltech.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.